Bone-Rad — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Bone-Rad Therapeutics is a development-stage biotech company pioneering a novel treatment for bone tumors, particularly spinal metastases. Its lead product, Spine-Rad™ Cement, integrates a radioactive isotope (Phosphorus-32) into standard bone cement to deliver localized radiation while mechanically reinforcing the bone, potentially improving efficacy and patient quality of life. Founded in 2016 based on technology licensed from the University of California in 2010, the company is currently in a start-up funding phase, seeking investment to advance its platform. It targets a significant market opportunity driven by an aging population and the high prevalence of spinal involvement in metastatic cancer.

OncologyMusculoskeletal

Technology Platform

Brachytherapy bone cement incorporating radioactive Phosphorus-32 (P-32) into PMMA bone cement for combined mechanical stabilization and localized tumor irradiation.

Opportunities

The aging global population and improved cancer survival rates are increasing the prevalence of patients with bone metastases, creating a growing addressable market.

Spine-Rad Cement's one-step procedure offers a potential improvement in patient quality of life and treatment logistics over the current two-step standard, which could drive clinical adoption and justify a premium price.

The platform technology could later be expanded to treat metastatic disease in other bones beyond the spine.

Risk Factors

The company faces high development and regulatory risk as a novel combination product, requiring complex and costly clinical trials.

Its progress is entirely dependent on securing external investment, creating significant financing risk.

Even if approved, commercial adoption may be slow due to the need to change established clinical practice and integrate handling of radioactive materials into hospital workflows.

Competitive Landscape

Direct competitors include other companies developing radiopharmaceuticals or device-based treatments for bone metastases, but Spine-Rad's specific combination approach appears novel. Its primary competition is the entrenched standard of care: the separate but sequential use of vertebroplasty/kyphoplasty devices (from companies like Medtronic, Stryker) and external beam radiation therapy systems. It must demonstrate superior efficacy, convenience, or cost-effectiveness to displace this established paradigm.

More companies in Radiopharmaceuticals →More companies in Ireland →